Full Press Release Details
Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
CA, June 23, 2023 - LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) ("LIXTE"
or the "Company") announced today that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq")
that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently
meets all other applicable criteria for continued listing.
June 24, 2022, Nasdaq notified LIXTE that its common stock failed to maintain a minimum bid price of $1.00 per share over the previous
30 consecutive trading days as required by the Listing Rules of Nasdaq. In order to address this issue, the Company effected a 1-for-10
reverse stock split of its issued and outstanding shares of common stock on Friday, June 2, 2023, as a result of which the Company's
common stock commenced trading on a post-split basis beginning on Monday, June 5, 2023.
LIXTE Biotechnology Holdings, Inc.
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing
and commercializing cancer therapies. LIXTE has achieved a breakthrough demonstrating that its first-in-class lead clinical PP2A inhibitor,
LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical
data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies
or immunotherapies. LIXTE's new approach has no known competitors and is covered by a comprehensive patent portfolio. Initial proof-of-concept
clinical trials are in progress.
more information about LIXTE, contact:
Phone: (631) 830-7092; Investor Phone: (888) 289-5533
Inc. Investor Relations
Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962